McAdams Wright Ragen’s Lineage Cell Therapeutics LCTX Stock Holding History

McAdams Wright Ragen’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$31K	Buy	+12,390	New	+$29.8K	﹤0.01%	421

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

DWM

Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $666M AUM 45.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

McAdams Wright Ragen's LCTX Position: Q3 2014 in Review

McAdams Wright Ragen opened a new position in Lineage Cell Therapeutics (LCTX) in Q3 2014: 12,390 shares worth $31K. The stake represents ﹤0.01% of the portfolio and ranks #421 among its holdings.

57 funds tracked by Wall St. Rank hold LCTX as of Q3 2014.

McAdams Wright Ragen held 12,390 shares of Lineage Cell Therapeutics worth $31K as of Q3 2014.
Lineage Cell Therapeutics was a new McAdams Wright Ragen position in Q3 2014.
Lineage Cell Therapeutics made up ﹤0.01% of McAdams Wright Ragen's portfolio in Q3 2014, its #421 holding.
57 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2014.

Based on McAdams Wright Ragen's 13F filing for Q3 2014, filed 14 Nov 2014.